Pt(IV)Ac-POA: new platinum compound Induced caspase independent apoptosis In B50 neuroblastoma stem cells by Ferrari, B et al.
                                         Journal of Embryology & Stem Cell Research 
ISSN: 2640-2637                                                  
 
Pt(IV)Ac-POA: New Platinum Compound Induced Caspase 
Independent Apoptosis In B50 Neuroblastoma Stem Cells 




Pt(IV)Ac-POA: New Platinum Compound Induced Caspase 
Independent Apoptosis In B50 Neuroblastoma Stem Cells 
 
 
Ferrari B1, Camuso S1, Priori EC1, De Luca F1, Roda E1,3, Osella D2 
and Bottone MG1* 
1Department of Biology and Biotechnology, University of Pavia, Italy 
22Department of Sciences and Technological Innovation (DiSIT)"University of Eastern 
Piedmont, Italy 
3Laboratory of Clinical & Experimental Toxicology, Pavia Poison Centre, National Toxicology Information Centre, 
Toxicology Unit, ICS Maugeri Spa, IRCCS Pavia, Italy 
 
*Corresponding author: Maria Grazia Bottone, Department of Biology and Biotechnology, University of Pavia, Via 
Ferrata 9, 27100, Pavia, Italy, Tel: 3388527987; Email: bottone@unipv.it 
 
Abstract 
Neuroblastoma is a tumour that affects adults and children, characterized by a stem cells component. To date, cisplatin is 
the main antitumor agent used in the clinical treatment of this tumour; however, it induces side effects such as 
neurotoxicity in healthy cells and induces chemo resistance to therapy in cancer cells. New platinum-based compounds, 
platinum (II) have recently been synthesized, and due to their chemical characteristics, they are able to identify new 
cellular targets. These complexes act as prodrugs and performing their cytotoxic effect as platinum (II) after a reduction 
reaction within the hypoxic tumour cells. Among these prodrugs, Pt(IV)Ac-POA appears to be very promising, thanks to 
the presence of ligand (2-propinyl)octanoic acid (POA), which acts as an inhibitor of histone deacetylase (HDACi) and 
leads to the increase of histone acetylation, decreasing the interactions between histone and DNA, so as to produce 
chemo-sensitization to DNA-damaging agents. The greater cytotoxic effect of Pt(IV)Ac-POA on tumour cells, would 
therefore be mainly due to the mechanism of inhibition of histone deacetylase, which would increase the accessibility of 
DNA to platination mechanisms that induce cell death. In this study the results show that Pt(IV)Ac-POA, used at a 
concentration ten times lower than cisplatin, can induce apoptosis in B50 cells in culture both through the intrinsic 
pathway and through the independent caspase pathway. The data, obtained by immunohistochemical techniques in 
fluorescence microscopy, show that treatment with Pt(IV)Ac-POA has a greater proapoptotic effect on stem cells 
compared to the cisplatin standard treatment.  
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Cisplatin is one of the most active chemotherapeutic 
drug used in the treatment of different type of solid 
cancer, including some nervous system tumours, such as 
Neuroblastoma [1]. Neuroblastoma is a frequently extra-
cranial tumour in infancy, representing 8-10% of all 
cancer in childhood. To date, cisplatin is largely employed 
in Neuroblastoma treatment, but despite its benefit, its 
used is hampered by severe systemic side effects and the 
onset of drug resistance [2-4]. For this reason, in the last 
years the goal of biomedical research has been the 
synthesis of new antitumor agents, with the same 
antitumor effect of the reference drug, but associated to 
less systemic toxicity.  
 
To overcome limits of classical oncotherapy, new 
platinum (IV) pro drugs have been synthesised. The 
Pt(IV) complexes act as pro drugs and reducing 
themselves to cytotoxic analogues of Pt(II) inside hypoxic 
tumour cells [5-7]. Among these, the new Pt(IV)Ac-POA 
pro drug represents a promising tool, bearing as axial 
ligand (2-propynyl) octanoic acid (POA), an histone 
deacetylase inhibitor (HDACi), Pt(IV)Ac-POA is able to 
produce a synergistic action in the hypoxic tumour cell 
microenvironment. Indeed, HDAC inhibition increases 
histone acetylation, decreasing histone-DNA interactions 
and allowing for chemo-sensitization versus DNA-
damaging agents [8-10]. The new prodrug has showed 
also a higher activity due to the high cellular accumulation 
by virtue of high lipophilicity and to the inhibition of 
histone deacetylase which leads to increased exposure of 
nuclear DNA, thereby permitting higher platination levels 
and promoting cancer cells death.  
 
In this study we evaluated the effect of the new 
Pt(IV)Ac-POA on the B50 Neuroblastoma rat cells, 
focusing on the activation of different cell death pathways 
and the morphological and functional changes inducted 
by treatment. 
 
The B50 neuronal cell line offer several advantages to 
the study of neurons in culture, in fact they are simple to 
grow, to differentiate and to transfect. Concerning to our 
research, B50 cells have been extensively used in the 
study of death and toxicology.  
 
Materials and Methods 
B50 Neuroblastoma rat cells were cultured in 75 cm2 
flask, in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with L-glutamine (2 mM), penicillin 100 IU 
ml-1, streptomycin (100 mg l-1) and 10% fetal bovine 
serum (FBS), and at 37°C in a 5% CO2 humidified 
chamber. 
 
Cells were seed on glass coverslips placed in a 6 multi-
well and then treated with cisplatin at 40 µM or Pt(IV)Ac-
POA at 4 µM for 48h at continuous exposure. These 
concentrations for cisplatin and Pt(IV)Ac-POA were based 
on previous works and obtained by IC50 analysis, 
respectively [11,12]. 
 
After treatment with cisplatin (40 µM) and Pt(IV)Ac-
POA (4 µM) for 48h at continuous exposure an 
immunohistochemistry detection for Bax, Bcl-2 and AIF 
was performed, associated with a labelling for the 
mitochondria and a counterstained with Hoechst 33258 
for the nuclei (Table 1). Images were obtained by an 
Olympus BX51 microscope equipped with a 100-W 
mercury lamp and used under the following conditions: 
330-385 nm excitation filter (excf), 400 nm dichroic 
mirror (dm) and 420 nm barrier filter (bf) for Hoechst 
33258; 450-480 nm excf, 500 nm dm and 515 nm bf for 
the fluorescence of Alexa 488; 540 nm excf, 580 nm dm 
and 620 nm bf for Alexa 594. Images were then recorded 
with an Olympus MagniFire camera system and processed 
with the Olympus Cell F software. 
 
Antigen Primary antibody Dilution in PBS Secondary antibody Dilution in PBS 
Bax 
Polyclonal rabbit (Santa Cruz 
Biotechnology) 
1:200 
Anti-rabbit IgG1 Alexa Fluor 594 
(Molecular Probes, Invitrogen) 
1:200 
Bcl-2 
Polyclonal rabbit (Santa Cruz 
Biotechnology) 
1:200 
Anti- rabbit IgG1 Alexa Fluor 594 
(Molecular Probes, Invitrogen) 
1:200 
AIF 
Polyclonal rabbit (Cell Signaling 
Technology) 
1:200 
Anti- rabbit IgG1 Alexa Fluor 594 
(Molecular Probes, Invitrogen) 
1:200 
Mitochondria Human autoimmune serum a 1:200 
Anti-human IgG1 Alexa Fluor 488 
(Molecular Probes, Invitrogen) 
1:200 
Table 1: Primary and secondary antibodies used for immunocytochemical reactions at fluorescence microscope 
Rangone, et al. [12]. 
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Differences between control and treated samples were 
analysed, evaluating three independent experiments for 
each condition and protein analysed. The percentage of 
mean fluorescence intensity was calculated with ImageJ 
software and the obtained scores were expressed as the 
mean ± SEM (standard error of mean). Data differences 
were analysed for statistical significance by one-way 
ANOVA and post hoc Bonferroni’s test (software package 
GraphPad Prism Inc.). ρ values ranging from < 0.001 to < 
0.05 were considered statistically significant. 
 
Results 
To analyse the activation of cell death pathways, 
following treatment with cisplatin at 40 µM or Pt(IV)Ac- 
POA 4 µM, immunocytochemical reactions were 
conducted to put in evidence the proteins involved in 
these processes: Bax, Bcl-2 and AIF. 
 
After immunolabelling, in the B50 control cells, Bax 
(red fluorescence) was located in the cytoplasm and not 
localized with the mitochondria represented by green 
fluorescence (Figure 1). On the contrary, after both 
treatments, the Bax-immunolabelling was distributed 
nearby the mitochondria, where a clear colocalization of 
the Bax fluorescence with the organelles was observed. 
Semi quantitative analysis of the immunofluorescence 
intensity of Bax, showed an increased intensity in cells 
treated with Pt(IV)Ac-POA, compared to the control and 




Figure 1: Bax protein analysis. B50 cells in control condition and after treatment with cisplatin 40 µM or Pt(IV)Ac-
POA 4 µM. Green fluorescence for mitochondria, red for Bax and Hoechst 33258 counterstaining for the nuclei in blue. 
Inserts show detail of immunolobelling in control and in apoptotic cells. Bars: 40 µm. Histograms showed the 
percentage of mean fluorescence intensity per cells normalised to control (Ctr). Statistical analysis: number of 
observations per control and treated samples, and cisplatin vs Pt(IV)Ac-POA: *ρ < 0.05, ***ρ < 0.001. 
 
 
Images reported in Figure 2 show a double 
immunolabeling for Bcl-2, marked in red, and the 
mitochondria, green fluorescence. In B50 control cells, 
immunolabelling for Bcl-2 protein was distributed in the 
cytoplasm and any colocalization with the mitochondria 
fluorescence was detectable. After treatment with 
cisplatin at 40 µM and Pt(IV)Ac-POA at 4 μM, respectively, 
Bcl-2 translocated to the mitochondria in early apoptosis, 
while its expression decreases, resulting almost absent in 
late apoptosis, as can be seen in the inserts. To note, in 
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cells exposed to treatment with cisplatin, an increasing in 
Bcl-2 fluorescence was observed and corroborated by 
semi quantitative analysis. In fact, B50 cells that show a 
control-like phenotype after treatment show an increase 
in fluorescence for the protein under examination. 
 
 
Figure 2: Bcl-2 protein analysis. B50 cells in control condition and after treatment with cisplatin 40 µM or Pt(IV)Ac-
POA 4 µM. Green fluorescence for mitochondria, red for Bcl-2 and Hoechst 33258 counterstaining for the nuclei in 
blue. Inserts show detail of immunolobelling in control and in apoptotic cells. Bars: 40 µm. Histograms showed the 
percentage of mean fluorescence intensity per cells normalised to control (Ctr). Statistical analysis: number of 
observations per control and treated samples, and cisplatin vs Pt(IV)Ac-POA: ***ρ < 0.001. 
 
 
Immunolabel for AIF, red fluorescence, revelled that in 
B50 control cells, AIF fluorescence localizes with the 
mitochondria (green fluorescence) (Figure 3). After 
treatment with cisplatin at 40 µM or Pt(IV)Ac-POA at 4 
µM, the fluorescence related to AIF was no longer 
associated with labelling for mitochondria, but was found 
at the nuclear level which, following treatment, appears 




Figure 3: AIF protein analysis. B50 cells in control condition and after treatment with cisplatin 40 µM or Pt(IV)Ac-
POA 4 µM. Green fluorescence for mitochondria, red for AIF and Hoechst 33258 counterstaining for the nuclei in blue. 
Inserts show detail of immunolobelling in control and in apoptotic cells. Magnifications: 40x, inserts: 100x. 
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At last, in each condition analysed, a severe alteration 
in mitochondria structure were observed after both 
treatments compared to control. Indeed, in control cells 
mitochondria were characterized by a fusiform aspect 
and a homogeneous localization in the cytoplasm. 
Following treatment with cisplatin or Pt(IV)Ac-POA, the 
mitochondria lose their structure, appeared smaller and 
more rounded, clustering in dense masses around cells 
nuclei. A strong reduction in the number and in the cell 
size were evident after exposure Pt(IV)Ac-POA compared 
to control and cisplatin-treated cells. In particular, after 
cisplatin exposure some cells showed a treatment-
resistant phenotype, the mitochondria maintain 
morphology comparable to that found in control cells and 
proteins of interest remained in the physiological 
compartment. This data was not observed after treatment 
with Pt(IV)Ac-POA or at least was detected in a minor 
way compared to cisplatin, suggesting a greater 
proapoptotic effect of the new compound.  
 
Conclusion 
Results presented in this work show that the prodrug 
can activate both the apoptotic pattern in B50 cell lines: 
the intrinsic apoptotic pathway and the independent 
caspase pattern. After treatment with Pt(IV)Ac-POA a 
morphological change in mitochondria, which undergo 
fission, were observed associated to i) an increase in the 
Bax protein level, ii) the translocation of AIF from the 
mitochondria to the nucleus and iii) a decrease in Bcl-2. 
Quantified values, which are statistically significantly, 
corroborates the greater effect of the new compound, 
active already at 4 µM, than cisplatin (40 µM). After 
Pt(IV)Ac-POA 4 µM treatment, as had already been 
demonstrated by Rangone, et al. [12], the number of cells 
dying due to apoptosis or autophagy is also greater, 
compared to the standard treatment with cisplatin, 
where, the cells that do not show an apoptotic 
morphology and cells are characterized by an increasing 
in Bcl-2 protein expression, suggesting a cisplatin-chemo 
resistance. 
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